| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MGMT |
| Uniprot No | P16455 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-207aa |
| 氨基酸序列 | MDKDCEMKRT TLDSPLGKLE LSGCEQGLHE IKLLGKGTSA ADAVEVPAPA AVLGGPEPLM QCTAWLNAYF HQPEAIEEFP VPALHHPVFQ QESFTRQVLW KLLKVVKFGE VISYQQLAAL AGNPKAARAV GGAMRGNPVP ILIPCHRVVC SSGAVGNYSG GLAVKEWLLA HEGHRLGKPG LGGSSGLAGA WLKGAGATSG SPPAGRN |
| 预测分子量 | 25 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于MGMT重组蛋白的示例文献(注：内容为示例性概括，非真实文献)：
---
1. **标题**: "Expression and purification of recombinant human O6-methylguanine-DNA methyltransferase (MGMT)"
**作者**: Smith A, et al.
**摘要**: 研究报道了在大肠杆菌中高效表达人源MGMT重组蛋白的优化方法，通过His标签亲和层析纯化，验证了其修复DNA烷基化损伤的酶活性，为体外药物筛选提供基础。
2. **标题**: "Structural insights into MGMT-mediated DNA repair by crystal analysis"
**作者**: Jones B, et al.
**摘要**: 通过X射线晶体学解析重组MGMT蛋白的三维结构，揭示了其活性位点与O6-甲基鸟嘌呤的特异性结合机制，为设计MGMT抑制剂增强化疗效果提供理论依据。
3. **标题**: "MGMT overexpression confers temozolomide resistance in glioblastoma models"
**作者**: Lee C, et al.
**摘要**: 利用重组MGMT蛋白转导胶质瘤细胞，证明其过表达显著降低替莫唑胺(TMZ)的细胞毒性，提示MGMT活性是预测化疗耐药的关键生物标志物。
---
(如需真实文献，建议通过PubMed或Web of Science以关键词"recombinant MGMT protein"检索。)
**Background of MGMT Recombinant Protein**
MGMT (O⁶-methylguanine-DNA methyltransferase) is a DNA repair enzyme critical for maintaining genomic stability by reversing alkylation damage at the O⁶ position of guanine. This specific lesion, often induced by alkylating agents (e.g., temozolomide or nitrosoureas), disrupts DNA replication and triggers cytotoxic or mutagenic effects. MGMT functions as a "suicide enzyme," transferring the alkyl group from damaged DNA to its active-site cysteine residue, thereby irreversibly inactivating itself. This repair mechanism is pivotal in protecting cells from alkylation-induced toxicity but also contributes to resistance in cancer chemotherapy, as elevated MGMT levels in tumors diminish the efficacy of alkylating drugs.
In cancer biology, MGMT expression is epigenetically regulated, with promoter methylation silencing the gene in certain tumors. This methylation status is a predictive biomarker; for example, glioblastoma patients with MGMT-silenced tumors show better responses to temozolomide. Recombinant MGMT protein, produced via bacterial (e.g., *E. coli*) or eukaryotic expression systems, is widely used in research to elucidate DNA repair mechanisms, screen for MGMT inhibitors, or model resistance pathways. Its applications extend to gene therapy, where engineered MGMT variants (e.g., P140K mutant) are employed to protect hematopoietic stem cells during dose-intensified chemotherapy.
The development of MGMT recombinant tools has advanced personalized oncology and genome-editing studies, offering insights into tailoring chemotherapeutic regimens and improving therapeutic outcomes. However, challenges remain in balancing DNA repair modulation to avoid unintended mutagenesis or therapeutic resistance. Ongoing research focuses on optimizing MGMT-based strategies to enhance precision in cancer treatment and reduce off-target effects.
×
